Comparative Pharmacology
Head-to-head clinical analysis: AN DTPA versus CIS MDP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN DTPA versus CIS MDP.
AN-DTPA vs CIS-MDP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AN-DTPA (pentetate calcium trisodium) is a chelating agent that binds to and removes heavy metals, such as plutonium, americium, curium, and other transuranic elements, from the body. It forms stable complexes with these metals, which are then excreted via the kidneys.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
1 gram by intravenous injection or infusion daily for 5 consecutive days, starting immediately after the end of radiotherapy.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5-2 hours in patients with normal renal function. Extended significantly in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Renal: >95% as unchanged drug via glomerular filtration. Biliary/fecal: <5%.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical